Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 664.00
-6.00 (-0.90%)
Sep 16, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -793 | -761 | -869 | -586 | -471 | - |
Depreciation & Amortization | 33 | 37 | 38 | 40 | 63 | - |
Other Operating Activities | 5 | 80 | 43 | 124 | 5 | - |
Change in Accounts Receivable | 2 | 15 | -3 | -3 | 44 | - |
Change in Inventory | -10 | -33 | -9 | -5 | 21 | - |
Change in Accounts Payable | 10 | 49 | 22 | -20 | -3 | - |
Change in Other Net Operating Assets | 60 | 79 | 18 | -112 | -62 | - |
Operating Cash Flow | -693 | -534 | -760 | -562 | -403 | - |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -3 | -47 | -8 | -19 | -228 | - |
Investment in Securities | -550 | -350 | - | - | -200 | - |
Other Investing Activities | - | - | - | - | -2 | - |
Investing Cash Flow | -553 | -397 | -8 | -19 | -430 | - |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | - | - | - | 73 | 328 | - |
Long-Term Debt Issued | - | 489 | - | - | 90 | - |
Total Debt Issued | 489 | 489 | - | 73 | 418 | - |
Short-Term Debt Repaid | - | -32 | -51 | - | - | - |
Long-Term Debt Repaid | - | -18 | -18 | -77 | -82 | - |
Total Debt Repaid | -42 | -50 | -69 | -77 | -82 | - |
Net Debt Issued (Repaid) | 447 | 439 | -69 | -4 | 336 | - |
Issuance of Common Stock | 751 | 817 | 17 | 22 | 2,329 | - |
Other Financing Activities | 191 | - | - | - | -7 | - |
Financing Cash Flow | 1,389 | 1,256 | -52 | 18 | 2,658 | - |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Miscellaneous Cash Flow Adjustments | -2 | -2 | -1 | - | -1 | - |
Net Cash Flow | 141 | 323 | -821 | -563 | 1,824 | - |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -696 | -581 | -768 | -581 | -631 | - |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -228.20% | -252.61% | -1422.22% | -952.46% | -168.72% | - |
Free Cash Flow Per Share | -71.88 | -66.01 | -95.40 | -74.37 | -236.54 | - |
Levered Free Cash Flow | -540.5 | -483.5 | -585.25 | -446.88 | -458 | - |
Unlevered Free Cash Flow | -527.38 | -474.13 | -579 | -440.63 | -453.63 | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 20 | 14 | 9 | 9 | 7 | - |
Cash Income Tax Paid | 2 | 2 | 2 | 2 | 2 | - |
Change in Working Capital | 62 | 110 | 28 | -140 | - | - |